MSS only

我们是谁

  • 4 月 5, 2022
    Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
  • 4 月 5, 2022
    SX-682和Nivolumab治疗RAS突变、MSS不可切除或转移性结直肠癌的STOPTRAFFIC-1试验
  • 4 月 5, 2022
    Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
  • 4 月 5, 2022
    Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer
  • 4 月 5, 2022
    A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER)
  • 4 月 5, 2022
    Trial Of Pembrolizumab And Nintedanib
  • 4 月 5, 2022
    Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.
  • 4 月 5, 2022
    AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
  • 4 月 5, 2022
    Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer
  • 4 月 5, 2022
    Ipilimumab, Maraviroc and Nivolumab (LUMINESCENCE)